JP2007022942A - Medical composition including mesophilic ionic liquid - Google Patents
Medical composition including mesophilic ionic liquid Download PDFInfo
- Publication number
- JP2007022942A JP2007022942A JP2005204553A JP2005204553A JP2007022942A JP 2007022942 A JP2007022942 A JP 2007022942A JP 2005204553 A JP2005204553 A JP 2005204553A JP 2005204553 A JP2005204553 A JP 2005204553A JP 2007022942 A JP2007022942 A JP 2007022942A
- Authority
- JP
- Japan
- Prior art keywords
- ionic liquid
- solubility
- compounds
- drugs
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
Description
本発明は、医薬品原体の新たな溶解剤としての常温性イオン性液体の利用方法を提供するものであり、更には常温性イオン性液体を溶解剤として利用する新規な医薬品粗生物の提供に関するものである。
The present invention provides a method for using a cold ionic liquid as a new solubilizer of a drug substance, and further relates to the provision of a novel crude drug product using the cold ionic liquid as a solubilizer. Is.
医薬品は、人体内に入って薬理作用を発揮するものであり、その送付方法としては、注射、経口投与、及び座剤、経皮、経肺など局所投与などが知られているが、いずれの投与法においても、安定した製剤が医薬品として必須な条件となる。
医薬品原体の製剤化において、薬剤を溶解することがその製剤化の過程で重要な要素であることは、本領域の研究者にとって共通したものである。さらに、注射剤はもちろんのこと、経口剤、局所剤においても、化合物の溶解性が、生体吸収性、バイオアベイラビリティーの制限要因を大きく上昇させることもよく知られた事実である。
Drugs enter the human body and exert pharmacological effects. As delivery methods, injection, oral administration, and local administration such as suppositories, transdermal, transpulmonary, etc. are known. Even in the administration method, a stable preparation is an essential condition as a pharmaceutical product.
It is common for researchers in this field that dissolution of a drug is an important factor in the formulation process of drug substance formulation. Furthermore, it is a well-known fact that the solubility of a compound greatly increases the limiting factors of bioabsorbability and bioavailability in oral preparations and topical preparations as well as injections.
しかし、医薬品原体には難溶性の化合物が多く、そのため、溶解状態を改善し、薬剤のバイオアベイラビリティーを増大させるために、様々な技術が改善されてきた。一般的には微粒子化して薬剤と用剤の接触面積をあげる方法がある。また、種々の溶解剤を添加して化合物の溶解性を向上させるものがある。溶解剤としては、界面活性剤、サイクロデキストリンなどが知られているが、まだまだ課題が多く、十分なものとは言い難いのが現状である。 However, there are many poorly soluble compounds in the drug substance, and various techniques have been improved to improve the dissolution state and increase the bioavailability of the drug. In general, there is a method of increasing the contact area between the drug and the agent by making fine particles. In addition, there are those that add various solubilizers to improve the solubility of the compound. Surfactants, cyclodextrins, and the like are known as solubilizers, but there are still many problems and it is difficult to say that they are sufficient.
一方、最近常温性イオン性液体が新たな溶媒として注目を浴びている。すなわち陽イオンと陰イオンがイオン結合をしている化合物で、常温において溶液状態を呈するものを常温イオン性液体と定義される。その際のイオンの組み合わせとしては、有機骨格を有する陽イオンと無機陰イオン、無機陽イオンと有機骨格を有する陰イオン、ともに有機骨格を有する陽、陰イオンの組み合わせが考えられる。これら1群の常温性イオン性液体は、種々の特性が報告されている。そのひとつとして、他成分を溶融する特性が知られている。しかし、この常温性イオン性液体の他の化合物を溶解する技術を医薬品化合物に応用した事例は、いまだ報告されていない。
On the other hand, room temperature ionic liquid has recently attracted attention as a new solvent. That is, a compound in which a cation and an anion have an ionic bond, and exhibits a solution state at room temperature, is defined as a room temperature ionic liquid. As a combination of ions at that time, a combination of a cation having an organic skeleton and an inorganic anion, an anion having an inorganic cation and an organic skeleton, and a combination of a cation having an organic skeleton and an anion can be considered. Various properties of these one group of room temperature ionic liquids have been reported. As one of them, the property of melting other components is known. However, there has not yet been reported a case in which the technology for dissolving other compounds of this room temperature ionic liquid is applied to pharmaceutical compounds.
本発明の解決課題は、医薬品用化合物の製剤過程、及びその薬剤の生体内バイオアベイラビリティーにおいて、薬物の新たな溶解技術を提供し、更にはバイオアベイラビリティーをあげることによって薬剤の持つ有用性を増大させる医薬組成物を提供することである。
The problem to be solved by the present invention is to provide a new drug dissolution technique in the preparation process of a pharmaceutical compound and in-vivo bioavailability of the drug, and further to increase the usefulness of the drug by increasing bioavailability. It is to provide a pharmaceutical composition that increases.
本発明者らは、イオン性液体のもつ化合物を溶解する性質に着目し鋭意研究し、非常に幅広い常温性イオン性液体が、難溶性が課題である多くの医薬品原体を、非常に幅広く溶解することを見出した。この常温性イオン性液体の持つ高い溶解性は、当初の予想を大きく上回るものであり、医薬品領域における溶解剤に大きな転機をもたらす可能性を提供している。即ち、本発明は、難溶性のために製剤化の困難性を抱える医薬品原体、あるいは難溶性のために、臨床使用時に課題を抱える医薬品に対して、画期的な溶解方法を提示するものであり、更には、有用性の高い新たな医薬組成物を提供するものである。
The present inventors have intensively studied paying attention to the property of dissolving the compound of the ionic liquid, and a very wide range of room-temperature ionic liquids can dissolve many drug substances that are difficult to dissolve. I found out. The high solubility of this room-temperature ionic liquid greatly exceeds the initial expectation, and offers the possibility of bringing about a great turning point for the solubilizer in the pharmaceutical field. That is, the present invention presents an epoch-making dissolution method for a drug substance that is difficult to formulate due to poor solubility, or for a drug that has problems during clinical use because of poor solubility. Furthermore, the present invention provides a new useful pharmaceutical composition.
本発明は、難溶性医薬品原体に対し、溶解改善を通じ製剤技術の改良方法を提供することができる。更にその新たな製剤により、医薬品原体の持つ有用性を高めた新規な医薬品の創製手段を提供する。
INDUSTRIAL APPLICABILITY The present invention can provide a method for improving formulation technology for poorly soluble drug substances through improved dissolution. Furthermore, the new formulation provides a means for creating a new drug with enhanced usefulness of the drug substance.
本発明に係るイオン性液体は、陽イオンと陰イオンの塩であって低温で液状となる物質であれば何でもよいが、特に常温において溶液状態を呈する常温性イオン性液体であることが好ましい。また、イオン性液体を特に限定はしないが、具体例として１−ｂｕｔｙｌ−３−ｍｅｔｈｙｌ−１Ｈ−ｉｍｉｄａｚｏｌｉｕｍ ｂｒｏｍｉｄｅに代表されるイミダゾリウム系イオン性液体、ピリジニウム系イオン性液体および脂肪族系イオン性液体等を利用することが可能である。 The ionic liquid according to the present invention may be any substance as long as it is a salt of a cation and an anion and becomes liquid at a low temperature, but is preferably a room temperature ionic liquid that exhibits a solution state at room temperature. In addition, the ionic liquid is not particularly limited, but specific examples include imidazolium-based ionic liquid, pyridinium-based ionic liquid, and aliphatic ionic liquid represented by 1-butyl-3-methyl-1H-imidazolium bromide. Etc. can be used.
また、本発明にかかわる医薬品としては特に限定されないが、製剤工程、臨床応用の中で、その化合物の持つ難溶性のために課題を抱えている化合物全般が、対象として可能であり、特に、ペプチドなどの生体高分子由来医薬品や天然物由来医薬品を対象とすることが可能である。
In addition, the pharmaceutical product according to the present invention is not particularly limited, but in the preparation process and clinical application, all compounds having problems due to the poor solubility of the compound can be used as a target. It is possible to target biopolymer-derived pharmaceuticals such as these and natural product-derived pharmaceuticals.
以下に、実施例及び実験例を挙げて、更に具体的に説明するが、本発明は必ずしもこれらに限定されるものではない。なお、本実施例および比較例における配合量の値は、全て質量％である。
Hereinafter, the present invention will be described more specifically with reference to examples and experimental examples. However, the present invention is not necessarily limited thereto. In addition, the value of the compounding quantity in a present Example and a comparative example is all the mass%.
（試験例１）
Ｐａｃｌｉｔａｘｅｌ（Ｔａｘｏｌ）のイミダゾリウム系イオン性液体に対する溶解性試験を検討した。Ｔａｘｏｌは植物由来の難溶性の注射制癌剤であり、卵巣がんなどに優れた効果を示す。しかし、その難溶性のために患者に投与する際には、界面活性剤であるポリオキシエチレンヒマシ油（クロモホールＥＬ）を溶解剤として添加しており、その溶媒による全身性のショックが頻繁に発症し、それを避けるために、３時間かけて点滴靜注、ショック発症予防剤の事前投与などが実施されており、きわめてコンプライアンスが悪い。そこで代表的なイオン性液体であるイミダゾリウム系イオン性液体に対するＴａｘｏｌの溶解度を検討した。
表１に用いたイミダゾリウム系イオン性液体リストアップした、イオン性液体０．１から〜０．５ｇを別々に秤量し、正確に秤量したＴａｘｏｌ原薬約１０〜２０ｇを加え、手で振りながら７０℃の水浴中で５分間加温する。不溶の場合は、イオン性液体を追加して更に加温した。溶解確認後、室温で３昼夜放置し、結晶の出ないことを確認した。表２その成績を記載した。
表２に溶解度を記載した。なお当該液体中でのＴａｘｏｌを抽出し、ＨＰＬＣで分析した結果、分解物はほとんど認められなかった。
(Test Example 1)
A solubility test of Paclitaxel (Taxol) in an imidazolium-based ionic liquid was examined. Taxol is a plant-derived poorly soluble injectable anticancer agent and exhibits excellent effects on ovarian cancer and the like. However, due to its poor solubility, polyoxyethylene castor oil (chromohol EL), a surfactant, is added as a solubilizing agent when administered to patients, and systemic shock due to the solvent is frequent. In order to avoid the onset, intravenous infusion and pre-administration of a shock onset preventive agent are performed over 3 hours, and the compliance is extremely poor. Therefore, the solubility of Taxol in imidazolium-based ionic liquid, which is a typical ionic liquid, was examined.
The imidazolium-based ionic liquid used in Table 1 was listed, and 0.1 to 0.5 g of ionic liquid was weighed separately, and about 10 to 20 g of accurately measured Taxol drug substance was added and shaken by hand. Warm in a 70 ° C. water bath for 5 minutes. When insoluble, the ionic liquid was added and further heated. After confirming dissolution, it was allowed to stand at room temperature for 3 days and nights to confirm that no crystals appeared. Table 2 shows the results.
Table 2 shows the solubility. In addition, as a result of extracting Taxol in the said liquid and analyzing by HPLC, the decomposition product was hardly recognized.
医薬品の創製には製剤化が必須であり、用いる溶媒により思わぬ副作用を発症する。イオン性液体は新たな溶解剤として有用であり、既存或いは新規な医薬品の溶解剤として利用可能である。
Formulation is essential for the creation of pharmaceuticals, and unexpected side effects occur depending on the solvent used. The ionic liquid is useful as a new solubilizing agent and can be used as a solubilizing agent for existing or novel pharmaceuticals.
Claims (2)
Pharmaceutical composition wherein the ionic liquid according to claim 1 is an imidazolium series
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005204553A JP4969065B2 (en) | 2005-07-13 | 2005-07-13 | Pharmaceutical composition containing room temperature ionic liquid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005204553A JP4969065B2 (en) | 2005-07-13 | 2005-07-13 | Pharmaceutical composition containing room temperature ionic liquid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007022942A true JP2007022942A (en) | 2007-02-01 |
| JP2007022942A5 JP2007022942A5 (en) | 2008-08-28 |
| JP4969065B2 JP4969065B2 (en) | 2012-07-04 |
Family
ID=37784185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005204553A Expired - Fee Related JP4969065B2 (en) | 2005-07-13 | 2005-07-13 | Pharmaceutical composition containing room temperature ionic liquid |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4969065B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016002368A (en) * | 2014-06-18 | 2016-01-12 | 日本電信電話株式会社 | Percutaneous drug delivery system |
| EP3213769A4 (en) * | 2014-10-30 | 2018-02-21 | Asahi Kasei Kabushiki Kaisha | Transdermal-absorption-promoter and transdermal-absorption-promoting supplement |
| WO2018230687A1 (en) * | 2017-06-16 | 2018-12-20 | 株式会社 メドレックス | Anti-inflammatory and analgesic drug for external use |
| WO2021070893A1 (en) | 2019-10-11 | 2021-04-15 | 東レ株式会社 | Pharmaceutical composition including temperature-responsive ionic liquid |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002003478A (en) * | 2000-06-20 | 2002-01-09 | Japan Science & Technology Corp | N-alkoxyalkyl imidazolium salt and ionic liquid and ionic gel composed of the imidazolium salt |
| JP2003062467A (en) * | 2001-08-24 | 2003-03-04 | Central Glass Co Ltd | Ion liquid composition |
| WO2004016588A1 (en) * | 2002-08-19 | 2004-02-26 | Biosignal Limited | Furanone derivatives and methods of making same |
| WO2004084627A2 (en) * | 2003-03-21 | 2004-10-07 | The University Of Alabama | Cellulose matrix encapsulation and method |
| WO2005025499A2 (en) * | 2003-09-05 | 2005-03-24 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
-
2005
- 2005-07-13 JP JP2005204553A patent/JP4969065B2/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002003478A (en) * | 2000-06-20 | 2002-01-09 | Japan Science & Technology Corp | N-alkoxyalkyl imidazolium salt and ionic liquid and ionic gel composed of the imidazolium salt |
| JP2003062467A (en) * | 2001-08-24 | 2003-03-04 | Central Glass Co Ltd | Ion liquid composition |
| WO2004016588A1 (en) * | 2002-08-19 | 2004-02-26 | Biosignal Limited | Furanone derivatives and methods of making same |
| WO2004084627A2 (en) * | 2003-03-21 | 2004-10-07 | The University Of Alabama | Cellulose matrix encapsulation and method |
| WO2005025499A2 (en) * | 2003-09-05 | 2005-03-24 | Cell Therapeutics, Inc. | Hydrophobic drug compositions containing reconstitution enhancer |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016002368A (en) * | 2014-06-18 | 2016-01-12 | 日本電信電話株式会社 | Percutaneous drug delivery system |
| EP3213769A4 (en) * | 2014-10-30 | 2018-02-21 | Asahi Kasei Kabushiki Kaisha | Transdermal-absorption-promoter and transdermal-absorption-promoting supplement |
| WO2018230687A1 (en) * | 2017-06-16 | 2018-12-20 | 株式会社 メドレックス | Anti-inflammatory and analgesic drug for external use |
| JPWO2018230687A1 (en) * | 2017-06-16 | 2020-04-23 | 株式会社 メドレックス | Anti-inflammatory analgesic external preparation |
| WO2021070893A1 (en) | 2019-10-11 | 2021-04-15 | 東レ株式会社 | Pharmaceutical composition including temperature-responsive ionic liquid |
| KR20220080076A (en) | 2019-10-11 | 2022-06-14 | 도레이 카부시키가이샤 | Pharmaceutical composition comprising temperature-responsive ionic liquid |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4969065B2 (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3689791B2 (en) | Novel compositions based on taxoids | |
| JP5587198B2 (en) | Freeze-dried pharmaceutical composition having improved stability, containing taxane derivative, and method for producing the same | |
| KR0136722B1 (en) | New compositions containing taxane derivatives | |
| WO2006134864A1 (en) | Solubilization preparation | |
| JP2008542260A (en) | Novel injectable composition and method for its preparation | |
| JP6356873B2 (en) | Taxane active ingredient-containing liquid composition and liquid formulation | |
| JP2010522730A (en) | Ibuprofen, complex of cyclodextrin and third agent, and method of use in pharmacy | |
| AU2002306329B2 (en) | Aqueous cilostazol preparation for injection | |
| JP4969065B2 (en) | Pharmaceutical composition containing room temperature ionic liquid | |
| JP2021519817A (en) | Liquid pharmaceutical preparation | |
| JP2007531725A (en) | Injectable composition for cancer treatment | |
| Prasad et al. | Elucidating the polymorphic behavior of curcumin during antisolvent crystallization: Insights from Raman spectroscopy and molecular modeling | |
| BR112013005763B1 (en) | 5A-ANDROSTANE-3SS, 5, 6SS-TRIOL INJECTION AND INJECTION PREPARATION METHOD | |
| WO2007009355A1 (en) | Paclitaxel injection and preparation method thereof | |
| CN102892410A (en) | Pharmaceutical composition of ibuprofen for injection | |
| US20170035831A1 (en) | Composition comprising bortezomib | |
| WO2007096900A1 (en) | Stable pharmaceutical composition of taxanes | |
| TW201936191A (en) | Pharmaceutical composition for sustained release delivery of buprenorphine | |
| JP2010030906A (en) | Chemical preparation of poorly water-soluble medicine, method for producing the medicine chemical preparation and method for producing diluted medicine chemical preparation | |
| KR20230079035A (en) | Formulations of Cabazitaxel | |
| JP6292267B2 (en) | Docetaxel formulation | |
| da Costa Bernardo Port et al. | Effect of vehicle composition on the preparation of different types of dapsone crystals for topical drug delivery | |
| JP2013194009A (en) | Docetaxel formulation | |
| JPWO2005014009A1 (en) | Glycyrrhizin high-concentration formulation | |
| TWI235669B (en) | Concentrated emulsifier composition for preparing DB67 Silatecan injection solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080710 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20111020 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111227 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120327 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120403 |
|
| FPAY | Renewal fee payment (prs date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150413 Year of fee payment: 3 |
|
| R150 | Certificate of patent (=grant) or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |